According to the Centers for Disease Control and Prevention, an estimated 29.1 million people, or 9.3% of the U.S. population, have diabetes. Left untreated, diabetes can lead to unnecessary hospitalizations and death. While Diabetes ranks as the seventh leading cause of death in the U.S., many people with diabetes actually die from complications related to diabetes rather than the disease itself. In 2011, 85.3% of adults with diagnosed diabetes reported taking pills or insulin for their diabetes. But, the increasing cost of diabetes medications in the U.S. often leads patients to forgo or ration life-saving treatments.
American consumers face skyrocketing out-of-pocket costs for their prescription medications. Senate Bill 2019 – The Preserve Access to Affordable Generics Act (S. 2019) would lower these costs by stopping the anticompetitive practice of “pay-for-delay” deals, also known as “reverse payment agreements.” These schemes enable brand-name pharmaceutical companies to pay-off potential generic competitors to postpone launching lower cost generic medications. The Federal Trade Commission has estimated that eliminating these agreements would save consumers about $3.5 billion a year.
About four million Americans import medication for personal use each year because of high drug costs, according to the U.S. Centers of Disease Control and Prevention. Their actions, under most circumstances, are technically illegal, but not something over which the government prosecutes individuals. The law, however, is unjust and unfair and should be reformed so that people who buy medication from a pharmacy in a different country are not, technically, criminally liable. Think about it. The medication you take is 90% cheaper in a different country and you can’t afford it domestically. It’s available for import by mail from a licensed pharmacy that you can access on the Internet. Why should the act of importing it be illegal?